Proof-of-concept efgartigimod trial for AAV expected this year
Argenx is planning to launch a proof-of-concept clinical trial later this year to test its therapy efgartigimod, approved to treat another autoimmune disease, in people with ANCA-associated vasculitis (AAV). Data from proof-of-concept studies can help companies and their researchers decide whether to develop a medicine for a specific…